City Therapeutics Appoints Andrew Orth as CEO to Propel RNAi Innovation into Clinical Development

Cambridge, MA, January 07, 2025 (Business Wire) -- City Therapeutics, a biopharmaceutical leader in RNA interference (RNAi) medicine, has appointed Andrew Orth as Chief Executive Officer and director. Orth, with over 25 years of biopharmaceutical experience, including senior roles at Krystal Biotech and Alnylam Pharmaceuticals, will guide the company as it prepares to advance its first RNAi-based program into clinical trials by late 2025. His leadership is expected to drive strategic growth and strengthen City Therapeutics' position as a pioneer in next-generation RNAi therapies designed to address unmet medical needs across various diseases.

Read full article here.